NasdaqGS:APLSBiotechs
Apellis Pharmaceuticals (APLS) Q1 Profitability Reinforces Bullish Earnings Quality Narrative
Apellis Pharmaceuticals (APLS) opened Q1 2026 with total revenue of US$268.3 million and basic EPS of US$0.15, anchored by net income of US$18.7 million, while its trailing 12 month revenue stood at US$1.1 billion with basic EPS of US$1.05 and net income of US$133.3 million. Over recent quarters the company has seen quarterly revenue range from US$166.8 million to US$458.6 million and basic EPS swing between a loss of US$0.74 and a gain of US$1.71, which places this latest quarter within a...